Baxter Warning Letter Sprinkled With Repeat Observations

Baxter Healthcare landed an FDA warning letter that includes multiple repeat observations and issues related to test methods, CAPAs and over-infusion with its elastomeric infusion systems.
Devices & Diagnostics Letter